Drug Discovery & Development
Skip to
Drug Discovery and Development
Briefly about Drug Discovery
Basic academic research unravels fundamental new knowledge about health and disease, upon which all drug discovery efforts are based. To attract interest from global pharmaceutical companies and investors, academia increasingly needs to validate these biological insights by developing prototype drugs within an academic setting.
SciLifeLab hosts Sweden´s national Drug Discovery & Development platform (DDD) that combines ground-breaking academic science from all over Sweden with an industry-standard wet-lab infrastructure and experts in drug discovery. In close collaboration with the university innovation support systems, the DDD platform has an impressive track-record of creating spin-outs and partnerships based on small molecules, antibodies, oligonucleotides and new modality therapeutics.
SciLifeLab also hosts complementary techniques of relevance for drug discovery, e.g. through the CBGE platform. Moreover, the NMR facility at SciLifeLab can provide fragment-based screening by NMR which aims to identify small molecular fragments binding to a target protein.
Contact person
For general inquiries about drug discovery services at SciLifeLab, please contact Per or dddprojectproposal@scilifelab.se.
Platform Director
Drug Discovery & Development Platform
Karolinska Institutet
per.arvidsson@scilifelab.se
What we offer at SciLifeLab
Drug Discovery and Development
Integrated services are offered in the following areas:
- Consultation meetings in matters related to target-based drug discovery, toxicology, advice on design of preclinical proof of concept studies, PK and PK/PD studies, etc.
- Biophysical, biochemical, and cellular assays for probing the pharmacological response and selectivity of small molecule-, biological- and oligonucleotide-based therapeutics
- Protein production and engineering, selection of antibody-based binders from in-house phage-display libraries, selection of small molecule binders from DNA-encoded small molecule libraries containing billions of compounds, support with upscaling of protein-based therapeutics
- Medicinal and computational chemistry for small molecules, oligonucleotides, conjugated molecules, protein degraders, etc.
- Analysis of drug-like properties, drug metabolism, and pharmacokinetics for all kind of therapeutic modalities
Importantly, the researcher/customer retains all rights and ownership during this process.
Explore more
Chemical Biology and Genomic Engineering
The SciLifeLab units providing chemical biology and genome engineering offerings also support drug discovery projects in various ways.
The CBCS unit offers assay development and phenotypic- and biochemical screening of small molecule libraries, and the SNC unit offers screening of low-molecular weight fragments via NMR. These offerings can be used to repurpuse drugs and develop tool compounds. The CBCS unit also hosts the SciLifeLab Compound Collection and the SciLifeLab Compound Center.
The Chemical Proteomics unit offers various MS methods for mechanism-of-action elucidation and target identification and the CRISPR Functional Genomics unit offers gene-editing and large-scale genetic screens.
Explore more
Other Infrastructure Resources
RISE can test and assess the potential toxicities/hazards of emerging drug candidates, industrial chemicals, food additives and medical devices, contributing to safety assessments required for market approvals. They can also support interactions with relevant regulatory authorities and development of regulatory submissions in these areas.